GlassScriptPhysician profile
Alex E Rikhter
NPI 1346226784
$8,157.78
in general payments reported to CMS, 2019-2025
43 companies · $771 in 2025
The $771 reported for 2025 was more than what 81% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,421 · 2020: $1,498 · 2021: $2,318 · 2022: $875 · 2023: $868 · 2024: $408 · 2025: $771.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,046.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,046.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,443.09 | 2019-2025 | Wegovy, Rybelsus, Ozempic |
| Astrazeneca Pharmaceuticals LP | $1,027.61 | 2019-2025 | Breztri, Farxiga |
| Amarin Pharma, INC. | $1,012.56 | 2019-2023 | |
| Amgen INC. | $639.59 | 2019-2025 | Evenity, Prolia, Otezla |
| Janssen Pharmaceuticals, INC | $388.37 | 2021-2022 | |
| Pfizer INC. | $318.47 | 2019-2024 | |
| Biohaven Pharmaceuticals, INC. | $309.67 | 2020-2021 | |
| Kowa Pharmaceuticals America, INC. | $273.23 | 2022-2025 | Zoryve |
| Abbvie INC. | $269.50 | 2019-2020 | |
| Eisai INC. | $251.52 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $241.07 | 2020-2023 | |
| Precision Spine, INC. | $186.76 | 2023 | |
| Glaxosmithkline, LLC. | $185.71 | 2020-2025 | Shingrix, Arexvy |
| Axsome Therapeutics, INC. | $181.25 | 2023-2025 | Auvelity |
| Novartis Pharmaceuticals Corporation | $128.58 | 2021-2023 |
Show all 43 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alex Rikhter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.